

Minutes
Incontinence in Neurological Disease - GDG Meeting 2
Location: National Clinical Guideline Centre, Board Room
5th November, 2010

GDG		NCGC	
Christine Anderson	CA	Gill Ritchie	GR
Amelia Denny	AD	Sharon Swain	SS
Noreen Barker	NB	Philippe Laramee	PL
Clare Fowler	CF	Tamara Diaz	TD
Laura Graham	LGr	Lina Gulhane	LG
Simon Harrison	SH		
Doreen McClurg	DM	NCGC Observers	
Julie Vickerman	JV	Hati Zorba	HZ
Alun Williams	AW	Vicki Pollit	VP
Sue Woodward	SW	Richard Whittome	RW
NICE			
Andrew Gyton	AG		

1. Welcome

1.1. Welcome and Apologies

The meeting started at 10:30 a.m. The chair welcomed all and the meeting heard formal apologies for Paul Tophill, Keith MacDermott, Susie Orme and Allison Bardsley. The day's observers were introduced to meeting attendees and the GDG and technical team introduced themselves for the benefit for group members who had not attended the first meeting.

1.2. Declarations of Interest

There were no declarations of interest relevant to the day's agenda.

1.3. GDG 1 – Minutes and Notes

There were no amendments to the notes and minutes of GDG meeting 1, the GDG accepted the notes and minutes as a true and accurate reflection of the meeting's events.

1.4. Matters Arising

There were no matters arising from the minutes of the previous meeting. The Chair presented an overview of the agenda for the day's meeting and invited the technical team to deliver the day's presentations.

2. Presentations:

- 2.1. Method and presentation of reviews – Sharon Swain
- 2.2. Making Recommendations and Evidence to Recommendations – Gill Ritchie
- 2.3. Discussion Points – Simon Harrison

3. Evidence Review and Drafting of Recommendations

- 3.1. SS presented clinical evidence, and PL presented health economic evidence on the following clinical question:

3.1.1. What is the safety and efficacy of antimuscarinics compared with a) placebo/usual care b) other antimuscarinics? Recommendations were drafted for adults and also for children and young people.

3.2. SS presented clinical evidence on the following clinical question, there were no Health Economic considerations for this area:

3.2.1. What is the safety and efficacy of alpha adrenergic antagonists compared with a) other adrenergic antagonists b) placebo/usual care in neurological disease.

4. Economic Priorities

4.1. The GDG discussed and agreed the economic considerations for each clinical question that will be reviewed during the guideline. Discussions were led by Health Economist, PL.

5. Review and Agree Key Clinical Questions

5.1. The GDG, led by Senior Research Fellow, SS agreed the key clinical questions and search protocols for the following topics:

- 5.1.1. Intravesical Botulinum Toxin
- 5.1.2. Monitoring/Surveillance Protocols
- 5.1.3. Long Term Risk
- 5.1.4. Specialist Assessment
- 5.1.5. Catheter Valves
- 5.1.6. Pelvic Floor Muscle Training
- 5.1.7. Behavioural Training
- 5.1.8. Catheters

6. Close of Meeting

6.1. Any other business and next meeting

The next meeting of the Incontinence in Neurological Disease GDG will be held in the NCGC offices, on December 15th from 10:30 a.m. – 4:30 p.m. There being no further business the chair closed the meeting at 3:35 p.m.